3.88% 0.0262

Scynexis Inc (SCYX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché SCYX Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Scynexis Inc Stock (SCYX) Company Profile

Scynexis Inc

Healthcare (1166)

201-884-5485

1 EVERTRUST PLAZA, JERSEY CITY, NJ

Prossima data di guadagno

Ultimi documenti SEC

SCYX's Discussions on Twitter

Confronta SCYX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SCYX Scynexis Inc	0.701	34.52M	135.87M	72.20M	45.09M	1.42
RGC Regencell Bioscience Holdings Ltd	14.60	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	159.19	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.35	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	15.37	47.39B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	16.64	20.17B	16.54B	-1.64B	749.00M	-1.45

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-01-22	Iniziato	Guggenheim	Buy
2021-01-06	Iniziato	Cantor Fitzgerald	Overweight
2018-07-11	Aggiornamento	Needham	Hold → Buy
2018-06-27	Iniziato	Maxim Group	Buy
2017-10-24	Iniziato	Guggenheim	Buy
2017-07-10	Iniziato	ROTH Capital	Buy
2017-05-09	Downgrade	Needham	Buy → Hold
2017-03-03	Reiterato	RBC Capital Mkts	Outperform
2016-10-20	Iniziato	H.C. Wainwright	Buy
2016-10-07	Aggiornamento	WBB Securities	Buy → Strong Buy
2016-10-03	Ripresa	Brean Capital	Buy
2016-08-17	Iniziato	Guggenheim	Buy
2016-08-09	Reiterato	Needham	Buy
2016-08-09	Aggiornamento	WBB Securities	Speculative Buy → Buy
2016-03-28	Iniziato	Brean Capital	Buy
2015-12-29	Iniziato	WBB Securities	Speculative Buy
2015-11-16	Reiterato	RBC Capital Mkts	Outperform
2015-06-10	Iniziato	Needham	Buy
2014-05-29	Iniziato	Canaccord Genuity	Buy
2014-05-29	Iniziato	RBC Capital Mkts	Outperform

Mostra tutto

Scynexis Inc Borsa (SCYX) Ultime notizie

Scynexis Inc Azioni (SCYX) Dati Finanziari

Scynexis Inc (SCYX)

Scynexis Inc Stock (SCYX) Company Profile

Confronta SCYX con altri titoli

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Scynexis Inc Borsa (SCYX) Ultime notizie

Millennium Management LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jane Street Group LLC Buys New Holdings in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World

Northern Trust Corp Has $186,000 Stake in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Scynexis resumes dosing in Phase III MARIO study after lengthy delay - MSN

SCYNEXIS resumes Phase 3 antifungal study after FDA lift By Investing.com - Investing.com South Africa

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold - Insider Monkey

Scynexis resumes patient dosing in Phase 3 MARIO study - TipRanks

SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study - marketscreener.com

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX St - GuruFocus

GSK Involved in SCYNEXIS's Phase 3 Study Milestone Dispute | GSK Stock News - GuruFocus

SCYNEXIS resumes Phase 3 antifungal study after FDA lift - Investing.com Australia

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX Stock News - GuruFocus

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - The Manila Times

SCYNEXIS Restarts Critical Phase 3 Trial for Life-Threatening Infection, Faces $30M GSK Payment Battle - Stock Titan

SCYNEXIS Faces Challenges Amidst Antifungal Developments - TipRanks

Biosergen taps antifungal expert as board member - Biostock

FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval - Endpoints News

SCYNEXIS (NASDAQ:SCYX) Now Covered by Analysts at StockNews.com - Defense World

SCYNEXIS Inc reports results for the quarter ended March 31Earnings Summary - TradingView

Scynexis: Q1 Earnings Snapshot - CT Insider

SCYX Reports Strong Q1 Revenue, Progress in Clinical Trials | SCYX Stock News - GuruFocus

SCYX: Cash Reserves and Debt Repayment Update | SCYX Stock News - GuruFocus

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update | SCYX Stock News - GuruFocus

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

SCYNEXIS INC SEC 10-Q Report - TradingView

Sector Update: Health Care Stocks Fall Late Afternoon - marketscreener.com

News - Biostock

SCYNEXIS (SCYX) Projected to Post Earnings on Wednesday - Defense World

JPMorgan Chase & Co. Makes New Investment in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

SCYNEXIS, Inc. (NASDAQ:SCYX) Shares Sold by LPL Financial LLC - Defense World

Press Release Distribution & PR Platform - ACCESS Newswire

StockNews.com Begins Coverage on SCYNEXIS (NASDAQ:SCYX) - Defense World

GSK 'well positioned' for potential tariffs after beating forecasts - marketscreener.com

Aspergillosis Market Expected to Rise by 2034, Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, - Barchart.com

SCYNEXIS (NASDAQ:SCYX) Upgraded by StockNews.com to Hold Rating - Defense World

Blastomycosis Treatment Market Overall Study Report 2025-2032 | Janssen, Scynexis Inc, Novartis AG, Marck & Co. - openPR.com

Second-Generation Antifungal Aims to Address Invasive Fungal Disease - ContagionLive

Acute Vulvovaginal Candidiasis Treatment Market Poised - openPR.com

SCY-247 shows promise against resistant fungal infections By Investing.com - Investing.com South Africa

SCY-247 shows promise against resistant fungal infections - Investing.com

Breakthrough: SCYNEXIS's New Antifungal Drug Defeats 171 Resistant Fungal Strains in Latest Tests - Stock Titan

Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide - The Globe and Mail

SCYNEXIS (NASDAQ:SCYX) Lowered to Sell Rating by StockNews.com - Defense World

SCYNEXIS (SCYX) to Release Earnings on Thursday - Defense World

Research Analysts Issue Forecasts for SCYNEXIS FY2029 Earnings - Defense World

StockNews.com Downgrades SCYNEXIS (NASDAQ:SCYX) to Sell - Defense World

SCYNEXIS Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

SCYNEXIS Reports 2024 Financial Results and Updates - TipRanks

Scynexis Inc Azioni (SCYX) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a SCYX